European Primary Care Cardiovascular Society

Hypertension

Reduced blood pressure and incidence of hypertension with community-wide salt restriction

3' education - Sep. 16, 2019 - Paris, France - Prof. Jaime Miranda

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm
EPCCS Annual CV Summit

Recent updates to the international Hypertension Guidelines - where do they vary and what should we agree in primary care?

5' education - Mar. 21, 2019 - Lisbon, Portugal - Richard McManus & Richard Hobbs

ESC/ESH Guidelines on management of hypertension: what's new?

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

EPCCS

3' education - Feb. 8, 2019

May Measurement Month: Get involved to increase awareness on elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Hypertension - Can we agree on diagnostic and therapeutic thresholds?

10' education - Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Prof. Richard McManus, prof. Richard Hobbs and prof. Christos Lionis

Pharmacist intervention in American 'black barbershops' effective at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

3' education - Nov. 20, 2017 - AHA 2017 - Anaheim, CA, USA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

Good BP measurement depends more on appropriate technique than on absence of staff

3' education - Nov. 25, 2017 - AHA 2017 - Anaheim, CA, USA - Prof Karen Johnson - Memphis, TN, VS
##SCROLLER_ITEMS_FULL_TITLE##

What can be learned from the latest hypertension trials?

10' education - May 26, 2017

Identifying and treating patients with true hypertension

10' education - Feb. 24, 2016 - Prague - EPCCS 2015

Alcohol as a risk factor for hypertension

3' education - Nov. 20, 2014 - Brussels, Belgium - Prof. Daniel Duprez (Minnesota, USA) - EPCCS 2014
##SCROLLER_ITEMS_FULL_TITLE##

Renal denervation for truly resistant hypertension

3' education - Feb. 18, 2014 - London - 5-6 September 2013
##SCROLLER_ITEMS_FULL_TITLE##

What's new in hypertension guidelines?

3' education - Oct. 18, 2013 - EPCCS, September 5-6, 2013 - Richard McManus
##SCROLLER_ITEMS_FULL_TITLE##

What is the best method for diagnosing hypertension?

3' education - Sep. 7, 2012 - EPCCS 2012 - prof Richard McManus

Gradually increased risk of ASCVD with increasing SBP levels >90 mmHg

Literature - July 29, 2020 - Whelton SP et al. - JAMA Cardiol. 2020.

Presence of coronary artery calcium and risk of incident ASCVD events increased with increasing SBP levels in individuals with a SBP between 90 and 129 mmHg and no other traditional ASCVD risk factors.

Higher mortality risk in those with earlier onset of hypertension

Literature - July 14, 2020 - Wang C et al., - J Am Coll Cardiol. 2020.

In a case-control study of Chinese adults divided in age groups, earlier onset of hypertension was associated with higher risk of all-cause mortality and a trend for higher risk of CVD.

Reduction of antihypertensive medication noninferior to usual care in elderly

Literature - July 1, 2020 - Sheppard JP, et al. - JAMA 2020

Reduction of antihypertensive medication in patients ≥80 years who were on ≥2 antihypertensive medication was noninferior to usual care with regard to SBP control at 12 weeks.

Lowest risk of outcomes in HFpEF associated with SBP of 120-129 mmHg

Literature - May 28, 2020 - Selvaraj S et al., - J Am Coll Cardiol. 2020

This study showed that a SBP of 120 to 129 mmHg was associated with the lowest risk of adverse outcomes in HFpEF. SBP lowering does not explain the treatment effects of sacubitril/valsartan.

Continued ACEi and ARBs use in relation to coronavirus COVID-19 outbreak: an ESC statement

News - Mar. 16, 2020

The ESC Council on Hypertension has released a statement, strongly recommending to continue treatment of ACEi and ARBs in times of the COVID-19 pandemic, as evidence for harmful effects of these drugs in context of COVID-19 is lacking.

Diagnosis and management of hypertension in primary care | Bulgarian abstract

Jan. 30, 2020

Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Bulgarian.

BP elevation increases more rapidly with aging in women vs. men

Literature - Jan. 28, 2020 - Ji H, et al. - JAMA Cardiol. 2020

Sex-specific analysis of BP trajectories using data of >32,000 individuals indicates that BP elevation during life span increased faster in women than in men, starting at 30 years.

Dijagnostikovanje i lečenje hipertenzije u primarnoj zdravstvenoj zaštiti

Download - EPCCS Guidance translations
EPCCS Guidance translations

Download the Serbian version of the EPCCS Practical Guidance on Hypertension Management

Diagnosis and management of hypertension in primary care | Swedish abstract

Dec. 19, 2019

Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Czech.

Diagnosis and management of hypertension in primary care | Czech abstract

Dec. 11, 2019

Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Czech.

Superiority of thiazide or thiazide-like diuretics over ACEi as initial monotherapy in hypertension

Literature - Nov. 12, 2019 - Suchard MA, et al. - The Lancet 2019

A study using data of millions of patients showed that there are no differences in effectiveness between drug classes when initiating monotherapy for hypertension, with the exception of lower risk of MI, HHF and stroke with thiazide or thiazide-like diuretics when compared to ACEi.

Improved asleep ABP and reduced CVD risk with hypertension medication ingestion at bedtime

Literature - Oct. 31, 2019 - Hermida RC et al., - Eur Heart J 2019

A randomized clinical trial of hypertensive patients demonstrates that ingestion of hypertension medication at bedtime reduces asleep ABP and CVD event risk compared to ingestion upon awakening.